Remove Drugs Remove FDA Approval Remove Marketing
article thumbnail

Pfizer wins FDA approval for its $7B colitis drug

BioPharma Drive: Drug Pricing

Acquired with the buyout of Arena Pharmaceuticals, Velsipity enters a competitive market for ulcerative colitis pills.

article thumbnail

Bristol Myers gets key FDA approval for bone marrow disease drug

BioPharma Drive: Drug Pricing

A broadened clearance for Reblozyl in myelodysplastic syndromes should help Bristol Myers offset the looming loss of revenue from top-selling medicines set to soon lose market exclusivity.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Approves First At-Home Test for Chlamydia, Gonorrhea

Drugs.com

16, 2023 -- The first home test for chlamydia and gonorrhea will soon hit the market, following its approval Wednesday by the U.S. Food and Drug Administration. THURSDAY, Nov. People will be able to buy the Simple 2 Test over-the-counter at a.

article thumbnail

FDA approves Novartis’ copycat of blockbuster Biogen drug

BioPharma Drive: Drug Pricing

According to one analyst, the approval was the last hurdle keeping Sandoz’s Tyruko from directly competing in the U.S. market against Biogen’s inflammation-regulating medicine Tysabri.

article thumbnail

FDA approves Sage, Biogen drug for postpartum depression, but rejects wider use

BioPharma Drive: Drug Pricing

The agency turned back the companies' attempt to also win clearance for major depressive disorder, limiting its market potential.

article thumbnail

Topical Gel for Erectile Dysfunction Gets FDA Approval for Over-the-Counter Sale

Drugs.com

Food and Drug Administration has approved over-the-counter marketing for the product, called Eroxon, as a. TUESDAY, June 13, 2023 -- Men with erectile dysfunction will now have the option of using a topical gel to treat the condition.

article thumbnail

Roche follows AbbVie with FDA approval for dual-targeting lymphoma drug

BioPharma Drive: Drug Pricing

The approval of Columvi adds another “bispecific antibody” to the market, highlighting the fast research progress for drugs that target two proteins rather than one.